Ask AI
CELMoDs in Myeloma

CME

Experts Discuss CELMoDs in Myeloma

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: July 16, 2025

Expiration: January 15, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following best describes differences between novel CELMoDs and approved IMiDs in regulating myeloma cell proliferation and modulating immune responses?

2.

In your current practice, how likely would you be to consider a treatment for multiple myeloma that was FDA-approved based on MRD-negative CR data?

3.

Which investigational CELMoD is currently being evaluated in phase III trials enrolling patients with multiple myeloma in the post-ASCT maintenance and relapsed/refractory settings?